Physician profile
Jae Y Lee
NPI 1851365720
$9,227.73
in general payments reported to CMS, 2019-2025
46 companies · $1,258 in 2025
The $1,258 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $935 · 2020: $784 · 2021: $1,515 · 2022: $1,519 · 2023: $1,476 · 2024: $1,741 · 2025: $1,258.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,462 · Education: $13.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,461.64 |
| Education | $13.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,571.90 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,061.91 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $915.35 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $839.21 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $753.97 | 2019-2025 | |
| Amgen INC. | $572.65 | 2019-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $359.77 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Astellas Pharma US INC | $318.90 | 2019-2025 | Veozah, Myrbetriq |
| Bard Peripheral Vascular, INC. | $233.51 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $229.27 | 2019-2025 | Jardiance, Tradjenta |
| Abbott Laboratories | $206.27 | 2020-2023 | Freestyle Libre 3 |
| E.R. Squibb & Sons, L.L.C. | $183.57 | 2019-2024 | Eliquis |
| Janssen Pharmaceuticals, INC | $168.70 | 2019-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $166.68 | 2019-2024 | Verquvo, Belsomra, Gardasil 9 |
| Biohaven Pharmaceutical Holding Company LTD. | $165.57 | 2022 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jae Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.